Affiliation: Johnson and Johnson Pharmaceutical Research and Development
- Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspectiveDeborah Nicholl
Johnson and Johnson Pharmaceutical Services, Raritan, NJ 08869, USA
Curr Med Res Opin 26:943-55. 2010..Inpatient care to manage relapse of patients with schizophrenia contributes greatly to the overall financial burden of treatment. The present study explores to what extent this is influenced by duration of illness...
- Personal and social functioning in schizophrenia: defining a clinically meaningful measure of maintenance in relapse preventionDeborah Nicholl
Johnson and Johnson Pharmaceutical Services, LLC, Raritan, NJ 08869, USA
Curr Med Res Opin 26:1471-84. 2010....
- The burden of chronic low back pain with and without a neuropathic component: a healthcare resource use and cost analysisManeesha Mehra
Janssen Global Services LLC, Raritan, NJ 08869, USA
J Med Econ 15:245-52. 2012..This research addresses the need for population-based studies on the burden of chronic low back pain (CLBP) by examining healthcare service use and costs for patients with and without neuropathic components in the US population...